Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) – Research analysts at Zacks Investment Research increased their FY2017 earnings estimates for Can-Fite BioPharma in a research report issued to clients and investors on Wednesday. Zacks Investment Research analyst G. Zeng now anticipates that the biotechnology company will post earnings of ($0.59) per share for the year, up from their prior estimate of ($0.62).

CANF has been the subject of a number of other reports. Maxim Group restated a “buy” rating and issued a $7.00 target price on shares of Can-Fite BioPharma in a research note on Friday, September 1st. HC Wainwright set a $6.00 target price on Can-Fite BioPharma and gave the company a “buy” rating in a research note on Thursday, August 10th. Finally, ValuEngine lowered Can-Fite BioPharma from a “sell” rating to a “strong sell” rating in a research note on Thursday, September 7th.

Can-Fite BioPharma (CANF) opened at $1.44 on Monday. Can-Fite BioPharma has a 1-year low of $1.31 and a 1-year high of $2.67.

ILLEGAL ACTIVITY WARNING: “Research Analysts Set Expectations for Can-Fite BioPharma Ltd.’s FY2017 Earnings (CANF)” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at

About Can-Fite BioPharma

Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.

Receive News & Ratings for Can-Fite BioPharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma Ltd. and related companies with's FREE daily email newsletter.